Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, Pang WL, Kizhakeyil A, Wijaya GC, Huang DC, Nagarajan S, Chia BK, Cheah D, Liu YH, Zhang F, Rao HL, Tang T, Wong EK, Bei JX, Iqbal J, Grigoropoulos NF, Ng SB, Chng WJ, Teh BT, Tan SY, Verma NK, Fan H, Lim ST, Ong CK. Song TL, et al. Among authors: grigoropoulos nf. Blood. 2018 Sep 13;132(11):1146-1158. doi: 10.1182/blood-2018-01-829424. Epub 2018 Jul 27. Blood. 2018. PMID: 30054295 Free PMC article.
Thrombotic microangiopathy during carfilzomib use: case series in Singapore.
Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, Phipps C, Lee YS, Grigoropoulos NF, Lao Z, Surendran S, Teh EM, Goh YT, Chng WJ, Gopalakrishnan SK. Chen Y, et al. Among authors: grigoropoulos nf. Blood Cancer J. 2016 Jul 29;6(7):e450. doi: 10.1038/bcj.2016.62. Blood Cancer J. 2016. PMID: 27471866 Free PMC article. No abstract available.
The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, Tang T, Goh AZ, Ghosh A, Ng HJ, Gopalakrishnan S, Loh Y, Lim ST, Hwang W, Tan D, Goh YT. Phipps C, et al. Leuk Lymphoma. 2018 Oct;59(10):2336-2341. doi: 10.1080/10428194.2017.1422863. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345210
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.
Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng RJ, Wong EKY, Cheah DMZ, Chia BKH, Iqbal J, Grigoropoulos NF, Nairismägi ML, Ng CCY, Rajasegaran V, Hong H, Kim SJ, Cho J, Tse E, Mow B, Cai QC, Poon LM, Cai QQ, Tan J, Chan JY, Lim JX, Goh YT, Phipps C, Rötzschke O, Cheng CL, Ha JCH, Khoo LP, Loh YSM, Au-Yeung R, Chan TS, Kwong YL, Hwang W, Kim WS, Bei JX, Lin T, Ong CK, Lim ST. Lim JQ, et al. Among authors: grigoropoulos nf. Leukemia. 2020 Dec;34(12):3413-3419. doi: 10.1038/s41375-020-1000-0. Epub 2020 Aug 5. Leukemia. 2020. PMID: 32753688 Free PMC article. No abstract available.
No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma.
Ong SY, Lim JQ, Grigoropoulos N, Laurensia Y, Huang D, Chia BKH, Zhe DCM, Saraf SA, Cheng CL, Chuang WY, Kuo MC, Su YJ, Phipps C, Nagarajan C, Lee YS, Lung DTC, Shih LY, Goh YT, Lim ST, Ong CK. Ong SY, et al. Haematologica. 2021 Jun 1;106(6):1737-1739. doi: 10.3324/haematol.2020.269209. Haematologica. 2021. PMID: 33054138 Free PMC article. No abstract available.
Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.
Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng RJ, Wong EKY, Cheah DMZ, Chia BKH, Iqbal J, Grigoropoulos NF, Nairismägi ML, Ng CCY, Rajasegaran V, Hong H, Kim SJ, Cho J, Tse E, Mow B, Cai QC, Poon LM, Cai QQ, Tan J, Chan JY, Lim JX, Goh YT, Phipps C, Rötzschke O, Cheng CL, Ha JCH, Khoo LP, Loh YSM, Au-Yeung R, Chan TS, Kwong YL, Hwang W, Kim WS, Bei JX, Lin T, Ong CK, Lim ST. Lim JQ, et al. Among authors: grigoropoulos nf. Leukemia. 2021 Apr;35(4):1225. doi: 10.1038/s41375-021-01195-4. Leukemia. 2021. PMID: 33686199 Free PMC article. No abstract available.
CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.
Sun Y, Gao Y, Chen J, Huang L, Deng P, Chen J, Chai KXY, Hong JH, Chan JY, He H, Wang Y, Cheah D, Lim JQ, Chia BKH, Huang D, Liu L, Liu S, Wang X, Teng Y, Pang D, Grigoropoulos NF, Teh BT, Yu Q, Lim ST, Li W, Ong CK, Huang H, Tan J. Sun Y, et al. Among authors: grigoropoulos nf. Cancer Lett. 2021 Sep 2;521:268-280. doi: 10.1016/j.canlet.2021.09.002. Online ahead of print. Cancer Lett. 2021. PMID: 34481935 Free article.
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, Low ZS, Prasannan P, Gong C, Tan MGK, Nagarajan C, Huang D, Lu PW, Lim JQ, Barrans S, Ong CK, Lim ST, Chng WJ, Follows G, Hodson DJ, Du MQ, Goh YT, Tan SH, Grigoropoulos NF, Verma NK. Kizhakeyil A, et al. Among authors: grigoropoulos nf. Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0. Mol Cancer. 2021. PMID: 34654425 Free PMC article. No abstract available.
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy.
Tay T, Somasundaram N, Lim C, Khoo LP, Goh AZK, Lee YS, Liu X, Tao M, Quek R, Farid M, Poon E, Chan JYS, Chang EWY, Yang VSW, Goh YT, Tan D, Diong C, Grigoropoulos NF, Nagarajan C, Poon M, de Mel S, Jeyasekharan A, Chan EHL, Lee J, Chee YL, Lim ST, Tang T. Tay T, et al. Among authors: grigoropoulos nf. Cancer Rep (Hoboken). 2022 Sep;5(9):e1552. doi: 10.1002/cnr2.1552. Epub 2022 Apr 28. Cancer Rep (Hoboken). 2022. PMID: 35481622 Free PMC article.
26 results